Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Palantir’s Drop Depends on the Nasdaq Bearish Sentiment

By Chris Lau, InvestorPlace Contributor

PLTR stock is at the mercy of the Nasdaq’s steep sell-off, so wait for the correction to end before establishing a firm position.

Sell Inovio While You Still Can

By Chris Lau, InvestorPlace Contributor

INO stock is poised to fall further as the chances of a vaccine approval fall and its competitors widen their lead

What Happens to PSTH Stock After Mega-Deal Announced

By Chris Lau, InvestorPlace Contributor

Markets expect a big payout when Pershing finally puts its money to good use through a monster-sized acquisition.

Why Cassava Sciences Has Tremendous Upside Potential

By Chris Lau, InvestorPlace Contributor

SAVA stock has plenty of long-term potential after the company posted clinical results from its Alzheimer’s disease study.

Why Investors Should Consider a Long-Term Position in Palantir

By Chris Lau, InvestorPlace Contributor

Market panic pressured Palantir shares in the last week, as investors sold this money-losing software firm

Load More